Back
Cidara Therapeutics, Inc. Stock Predictions
The Next Gold Rush
DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at
Buy
69
CDTX
Cidara Therapeutics, Inc.
Last Price:
$221.38
Seasonality Move:
-10.12%
7 Day Trial
ALL ACCESS PASS
$
7
Exxon and Chevron Have an Unlikely New Competitor
DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available atCidara Therapeutics, Inc. Stock Forecast
-
Over the next 52 weeks, Cidara Therapeutics, Inc. has on average historically risen by 63.2% based on the past 10 years of stock performance.
-
Cidara Therapeutics, Inc. has risen higher in 3 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 30%
-
Is Cidara Therapeutics, Inc. Stock Undervalued?The current Cidara Therapeutics, Inc. [CDTX] share price is $221.38. The Score for CDTX is 69, which is 38% above its historic median score of 50, and infers lower risk than normal.
-
CDTX is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
Will Cidara Therapeutics, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Cidara Therapeutics, Inc. has on average historically risen by 63.2% based on the past 10 years of stock performance.
Cidara Therapeutics, Inc. Stock Rating
Buy
69
Cidara Therapeutics, Inc. (CDTX)
is a Buy
Is Cidara Therapeutics, Inc. overpriced?
-
Cidara Therapeutics, Inc. has risen higher in 3 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 30%
Cidara Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
cidara.com
52-Week Data
52-Week High:
221.42
52-Week Low:
15.22
Prediction Charts
Market Cap:
7B
Price in USD:
221.38
Volume:
0
Beta:
1.55
Technical Analysis
SMA50:
197.00
SMA100:
140.90
SMA200:
88.66
52-Wk Change:
958.22%
Stock Predictions
-
Is Cidara Therapeutics, Inc. stock public?Yes, Cidara Therapeutics, Inc. is a publicly traded company.
-
What is the Cidara Therapeutics, Inc. stock quote today?The Cidara Therapeutics, Inc. stock price is 221.38 USD today.
-
How to buy Cidara Therapeutics, Inc. stock online?You can buy Cidara Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Dec-23 | 220.85 | 220.86 | 220.91 | 220.66 |
| Dec-24 | 220.66 | 220.86 | 221.00 | 220.66 |
| Dec-26 | 220.86 | 220.80 | 221.00 | 220.73 |
| Dec-29 | 220.80 | 220.41 | 221.00 | 220.41 |
| Dec-30 | 220.60 | 220.80 | 220.80 | 220.40 |
| Dec-31 | 220.75 | 220.89 | 220.96 | 220.75 |
| Jan-5 | 221.11 | 221.32 | 221.42 | 221.07 |
| Jan-6 | 221.32 | 221.38 | 221.41 | 221.25 |
| Jan-7 | 221.38 | 221.38 | 221.38 | 221.38 |
| Jan-8 | 221.38 | 221.38 | 221.38 | 221.38 |
| Jan-9 | 221.38 | 221.38 | 221.38 | 221.38 |
| Jan-12 | 221.38 | 221.38 | 221.38 | 221.38 |
| Jan-13 | 221.38 | 221.38 | 221.38 | 221.38 |
| Jan-14 | 221.38 | 221.38 | 221.38 | 221.38 |
Cidara Therapeutics, Inc. Earnings
Cidara Therapeutics, Inc. Earnings Report: Per Share Cidara Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Cidara Therapeutics, Inc. Forecast Revenue Growth
Cidara Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Cidara Therapeutics, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $1.42 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.21 per share, and an increase next year of $0.59 per share.
* Cidara Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.